The knowledge generated in animal models and in human ex vivo studies related to VIP and its signaling pathways could be translated to clinical reality as two potential tools: as a therapeutic agent and as a biomarker in inflammatory/autoimmune diseases. Here, VIP is linked to autoimmune disease.